Securities Code: 002399 Securities Abbreviation: Hepalink Announcement No.: 2026-018 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announcement on Accrual of Asset Impairment Provisions for 2025 The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company"), in accordance with the "Enterprise Accounting Standards," the "Shenzhen Stock Exchange Stock Listing Rules," and the Company's relevant accounting policies, has conducted impairment tests on various accounts receivable, other receivables, prepayments, other non-current assets, long-term equity investments, fixed assets, intangible assets, development expenditures, and inventories within the scope of the consolidated financial statements for the year 2025. This was done to accurately and truthfully reflect the Company's assets and financial position. Based on the results of the impairment tests, impairment provisions have been accrued for assets showing signs of impairment, with details as follows: I. Overview of Accrual of Asset Impairment Provisions The asset items for which the Company has accrued impairment provisions for 2025 are primarily accounts receivable, other receivables, prepayments, other non-current assets, long-term equity investments, fixed assets, intangible assets, development expenditures, and inventories. The total impairment provisions accrued amount to RMB 217,676,152, as detailed in the table below:
| Project | 2025 Accrual Amount (RMB) |
|---|---|
| I. Credit Impairment Loss | |
| Impairment of accounts receivable | 17,976,334 |
| Impairment of other receivables | 56,235,475 |
| Impairment of other non-current assets | 8,656,064 |
| Subtotal | 82,867,873 |
| II. Asset Impairment Loss | |
| Impairment of long-term equity investments | 80,909,923 |
| Impairment of fixed assets | 6,953,867 |
| Impairment of intangible assets | 5,528,729 |
| Impairment of development expenditures | 4,907,589 |
| Impairment of inventories | 36,508,170 |
| Subtotal | 134,808,279 |
| Total | 217,676,152 |